Tiziana Life Sciences' (TLSA) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Tiziana Life Sciences' stock has been assigned a "sell (D-)" rating by Weiss Ratings, indicating potential concerns for investors.
• The company's stock price recently reached $1.94 and has fluctuated between a twelve-month low of $0.63 and a high of $2.60.
• Several institutional investors have increased their stakes in Tiziana Life Sciences, with notable acquisitions totaling approximately $316,000 across multiple quarters.

Tiziana Life Sciences (NASDAQ:TLSA - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Tiziana Life Sciences Price Performance

TLSA stock traded up $0.04 during mid-day trading on Friday, hitting $1.94. 88,506 shares of the company were exchanged, compared to its average volume of 349,646. Tiziana Life Sciences has a twelve month low of $0.63 and a twelve month high of $2.60. The firm has a fifty day simple moving average of $1.90 and a 200 day simple moving average of $1.66.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in shares of Tiziana Life Sciences in the 1st quarter valued at about $25,000. Marshall Wace LLP acquired a new position in shares of Tiziana Life Sciences in the 2nd quarter valued at about $39,000. ARS Investment Partners LLC acquired a new position in shares of Tiziana Life Sciences in the 3rd quarter valued at about $66,000. Bison Wealth LLC acquired a new position in shares of Tiziana Life Sciences in the 4th quarter valued at about $30,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Tiziana Life Sciences in the 1st quarter valued at about $156,000.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.